Back to today’s briefing

Story perspectives

Federal Panel Centralizes Lawsuits Over Weight Loss Drug Risks

12/16/2025

31 3

Summary

Story summary

A federal panel centralized lawsuits against Novo Nordisk and Eli Lilly in Philadelphia over weight loss drugs and non-arteritic anterior ischemic optic neuropathy.
The multidistrict litigation focuses on NAION claims and is separate from lawsuits about gastrointestinal side effects.
As of now, 30 federal cases are pending for optic neuropathy, with more than 40 in state court.

1 of 1

Story summary

A federal panel centralized lawsuits against Novo Nordisk and Eli Lilly in Philadelphia over weight loss drugs and non-arteritic anterior ischemic optic neuropathy.
The multidistrict litigation focuses on NAION claims and is separate from lawsuits about gastrointestinal side effects.
As of now, 30 federal cases are pending for optic neuropathy, with more than 40 in state court.